InflammX News
Press Releases
January 10, 2025
InflammX Therapeutics Announces Bausch + Lomb Option Agreement
· Baush + Lomb (B+L) has entered into an option agreement to acquire InflammX – including an upfront payment, regulatory and sales milestones plus high single digit royalties.
· The option can be exercised at any time based on inflection poins related to the clinical development program
· InflammX is in the process of raising a Series A round of $15-$20m to complete the iAMD clinical trial. First close of $5.75m has been completed.
· The unmet clinical need in iAMD alone is approximately 18m patients in the US with similar numbers in Europe. Since this is intended to be a global product numbers in the rest of the world yet to be determined.
· Acquisition by B+L provides significant investor returns which has seen ExSight Ventures invest in the first close.
· InflammX is in the process of seeking an additional $10-15m to complete the Series A.